Subpopulations of mononuclear leukocytes associated with inhibition of Ehrlich ascites tumor growth by treatment with Bothrops jararaca venom

Mediators of Inflammation

Volumn 13, Issue 1, 2004, Pages 29-32

  De Vieira Santos, Mariana Morena ^a   Da Silva, Reinaldo José ^a   Da Silva, Márcia Guimarães ^a   Fecchio, Denise ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Bothrops jararaca; Ehrlich ascites tumor; Mononuclear leukocytes; Venom

Indexed keywords

ANTINEOPLASTIC AGENT; BATROXOBIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CANCER INHIBITION; CONTROLLED STUDY; DATA ANALYSIS; DRUG EFFECT; DRUG INDICATION; EHRLICH ASCITES TUMOR; HISTOPATHOLOGY; KRUSKAL WALLIS TEST; LYMPHOCYTE SUBPOPULATION; MACROPHAGE; MALE; MONONUCLEAR CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; PERITONEAL CAVITY; PRIORITY JOURNAL; PROTEIN DEGRADATION; T LYMPHOCYTE SUBPOPULATION; TUMOR CELL CULTURE; TUMOR GROWTH;

ANIMALS; B-LYMPHOCYTES; BOTHROPS; CARCINOMA, EHRLICH TUMOR; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL DIVISION; CROTALID VENOMS; FLOW CYTOMETRY; LEUKOCYTES, MONONUCLEAR; MALE; MICE; NEOPLASM TRANSPLANTATION; PERITONEAL CAVITY; TIME FACTORS;

ANIMALIA; BOTHROPS; BOTHROPS JARARACA; SERPENTES;

EID: 2442540344     PISSN: 09629351     EISSN: None     Source Type: Journal    
DOI: 10.1080/09629350410001664770     Document Type: Article

References (14)

1. Silva RJ, Fecchio D, Barraviera B. Antitumor effect of snake venoms. J Venom Anim Toxins 1996; 2: 79-90.
2. Silva RJ, Fecchio D, Barraviera B. Effect of Crotalus durissus terrificus venom on the Ehrlich ascites tumor. J Venom Anim Toxins 1997; 3: 324-341.
3. Silva RJ, Silva MG, Vilela LC, Fecchio D. Antitumor effect of Bothrops jararaca venom. Med Inflamm 2002; 11: 99-104.
4. Silva RJ, Silva MG, Vilela LC, Fecchio D. Cytokine profile of Ehrlich ascites tumor treated with Bothrops jararaca venom. Med Inflamm 2002; 11: 197-201.
5. Gallagher G, Stimson WH, Findlay J, Al-Azzawi F. Interleukin-6 enhances the induction of human lymphokine-activated killer cells. Cancer Immunol Immunother 1990; 31: 49-52.
6. Iho S, Shau H, Golub SH. Characteristics of interleukin-6 enhanced lymphokine-activated killer cell function. Cell Immunol 1991; 135: 66-77.
7. Kitahara M, Kishimoto S, Hirano T, Kishimoto T, Okada M. The in vivo anti-tumor effect of human recombinant interleukin-6. Jpn J Cancer Res 1990; 81: 1032-1038.
8. Luger TA, Krutmann J, Kirnbauer R, et al. IFN-beta 2/IL-6 augments the activity of human natural killer cells. J Immunol 1989; 143: 1206-1209.
9. Okada M, Kitahara M, Kishimoto S, Matsuda T, Hirano T, Kishimoto T. H-6/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells. J Immunol 1988; 141: 1543-1549.
10. Russel SW, Doe WF, Cochrane CG. Number of macrophages and distributions of mitotic activity in regressing and progressing Moleney sarcomas. J Immunol 1976; 116: 164-166.
11. Russel SW, Doe WF, McIntosh AT. Functional characterization of a stable non-cytolytic stage of macrophage activation in tumors. J Exp Med 1997; 146: 1511-1520.
12. Sezzi ML, Beleli L, Nista A. Peritoneal macrophages and neoplastic cells. I. Macrophages activity induced by heavily-irradiated or heated-killed cancer cells. Oncology 1972; 26: 529-539.
13. Smyth MJ, Ortaldo JR, Bere W, Yagita H, Okumura K, Young HA. IL-2 and IL-6 synergize to augment the pore-forming protein gene expression and cytotoxic potential of human peripheral blood T cells. J Immunol 1990; 145: 1159-1166.
14. Rizzo E, Tuchiya HN. Cytopathic effect by Bothrops jararaca venom on animal cell cultures. Cienc Cult 1972; 24: 184-189.